Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone Marrow Toxicity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,238 result(s) found for: Bone Marrow Toxicity. Displaying page 1 of 62.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-006726-34 Sponsor Protocol Number: Anti TNF- aGvHD Start Date*: 2009-02-23
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Anti-TNF monoclonal antibody to treat acute GvHD refractary to the first line therapy with steroids
    Medical condition: Anti-TNF monoclonal antibody to treat acute GvHD refractary to the first line therapy with steroids
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010162 Complications of bone marrow transplant LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006146-34 Sponsor Protocol Number: 100505 Start Date*: 2008-04-30
    Sponsor Name:Stage Pharmaceuticals GmbH
    Full Title: Adoptive Immunotherapy of chemotherapy refractory CMV infections using Streptamer-isolated T cells after allogeneic bone marrow or peripheral blood stem cell transplantation: a phase I/II trial
    Medical condition: -chronic persistent CMV infection after allogeneic bone marrow or peripheral blood stem cell transplantation, refractory to antiviral chemotherapy
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001475-20 Sponsor Protocol Number: FILOCLL10-PREVENE Start Date*: 2018-12-21
    Sponsor Name:FILO
    Full Title: Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO PREVENE (PREemptive Venetoclax) trial
    Medical condition: Chronic lymphoid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001188-22 Sponsor Protocol Number: MIMMA Start Date*: 2013-09-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Interleukin 2 and zolendronic acid as maintaining treatment in multiple myeloma patients after autologous bone marrow transplant
    Medical condition: Multiple Myeloma patients underwent to autologous bone marrow transplant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001633-84 Sponsor Protocol Number: CFZ008 Start Date*: 2015-01-22
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphobla...
    Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10025230 Lymphatic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Temporarily Halted) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) FR (Ongoing) AT (Restarted) DK (Restarted) NL (Ongoing) SE (Ongoing) GR (Ongoing) PL (Ongoing) PT (Ongoing) BG (Ongoing) NO (Ongoing) CZ (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012189-30 Sponsor Protocol Number: BC1-09 Start Date*: 2009-10-30
    Sponsor Name:Algeta ASA
    Full Title: An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy
    Medical condition: Breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for further endocrine therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018044-18 Sponsor Protocol Number: TaxiumII Start Date*: 2012-06-22
    Sponsor Name:Meander MC
    Full Title: A randomised phase II study of repeated Rhenium-188 HEDP combined with Docetaxel versus Docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone’
    Medical condition: Men with castration resistant prostate cancer (CRPC) metastatic to bone
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10036921 Prostate carcinoma LLT
    16.1 100000004864 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001718-80 Sponsor Protocol Number: PRM-151G-101 Start Date*: 2016-02-18
    Sponsor Name:Promedior, Inc
    Full Title: A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)
    Medical condition: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018770-20 Sponsor Protocol Number: DC-005 Start Date*: 2010-05-21
    Sponsor Name:Oslo University Hospital
    Full Title: Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.
    Medical condition: Prostatic cancer patients who have received curative surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004824-19 Sponsor Protocol Number: ML21206 Start Date*: 2008-08-08
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study
    Medical condition: Chronic Lymphocytic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000916-27 Sponsor Protocol Number: RG_19-030 Start Date*: 2020-11-12
    Sponsor Name:University of Birmingham
    Full Title: Investigation into the combination of PLX2853 with ruxolitinib in patients with intermediate-2 or high risk myelofibrosis not receiving an adequate response with ruxolitinib alone.
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001643-39 Sponsor Protocol Number: 2215-CL-0302 Start Date*: 2017-02-09
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy...
    Medical condition: Subjects diagnosed with FLT3/ITD acute myeloid leukemia (AML) in CR1, including CRp and CRi, for whom a decision not to proceed with transplantation has been made, or a suitable donor could not be ...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) CZ (Completed) PL (Completed) PT (Completed) SE (Completed) GR (Completed) DK (Completed) HR (Ongoing) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005210-28 Sponsor Protocol Number: MMM02Study Start Date*: 2016-10-11
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study)
    Medical condition: primary myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004674-17 Sponsor Protocol Number: NL59901.078.17 Start Date*: 2017-10-17
    Sponsor Name:Princess Máxima Center for Pediatric Oncology
    Full Title: A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia...
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) BE (Ongoing) DK (Restarted) DE (Ongoing) CZ (Ongoing) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003631-36 Sponsor Protocol Number: RG_12-124 Start Date*: 2015-02-10
    Sponsor Name:University of Birmingham
    Full Title: CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL
    Medical condition: Chronic lymphocytic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10068852 B-cell chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-007593-31 Sponsor Protocol Number: prot 122 Start Date*: 2008-11-21
    Sponsor Name:FONDAZIONE RICERCA TRAPIANTO DI MIDOLLO OSSEO
    Full Title: Thiotepa dose finding study for allogeneic SCT in adult patients with high risk haematological malignancies
    Medical condition: bone marrow transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001434-34 Sponsor Protocol Number: MPN19H2 Start Date*: 2019-07-04
    Sponsor Name:Department of haematology, Zealand university hospital
    Full Title: Dual Vaccine Trial in Myeloproliferative Neoplasms
    Medical condition: Myeloproliferative Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10028576 Myeloproliferative disorder LLT
    20.1 100000004864 10036061 Polycythemia vera LLT
    20.1 100000004864 10015494 Essential thrombocythemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-004822-17 Sponsor Protocol Number: 17072008 Start Date*: 2008-12-10
    Sponsor Name:University Medical Center
    Full Title: Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patients
    Medical condition: Evaluation of the safety and efficacy of bortezomib combined with cyclophosphamide and dexametasone for induction and maintenance in bortezomib naive refractory on relapsed MM, stage II - III.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001447-31 Sponsor Protocol Number: 2018/2706 Start Date*: 2018-08-02
    Sponsor Name:Gustave Roussy
    Full Title: Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consol...
    Medical condition: Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) DK (Ongoing) NL (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004353-24 Sponsor Protocol Number: LAMVYX Start Date*: 2019-11-04
    Sponsor Name:Fundación PETHEMA
    Full Title: A phase II, multicentre, open label clinical trial to assess the efficacy and toxicity of induction and consolidation with CPX-351 for patients aged 60 to 75 years with secondary or high-risk acute...
    Medical condition: Newly diagnosed secondary or high risk AML
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:41:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA